Strong Buy Rating for Ocular Therapeutix Driven by Promising Axpaxli Program and Market Potential

Analyst Serge Belanger of Needham maintained a Buy rating on Ocular Therapeutix (OCUL – Research Report), retaining the price target of $14.00.

Serge Belanger has given his Buy rating due to a combination of factors influencing Ocular Therapeutix’s prospects. The company’s Axpaxli development program for wet age-related macular degeneration (wAMD) is progressing well, with the SOL-R trial nearing completion of patient enrollment and the SOL-1 trial on track for a top-line readout in the first quarter of 2026. This progress indicates a strong pipeline that could potentially meet significant market demand.
Moreover, the differentiation of Axpaxli’s pivotal programs, which may support claims of superiority over existing treatments like Eylea, adds to the stock’s appeal. The flexibility in dosing schedules and the program’s alignment with FDA guidelines further strengthen its competitive position. Despite competition from EyePoint Pharmaceuticals’ Duravyu, the large market opportunity and unmet need for extended wAMD treatments suggest that both products could succeed, supporting the Buy rating.

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of OCUL in relation to earlier this year.